Welcome to our dedicated page for Worthington Steel news (Ticker: WS), a resource for investors and traders seeking the latest updates and insights on Worthington Steel stock.
Worthington Steel, Inc. reports company news centered on value-added steel processing, quarterly and annual operating results, dividends, conference calls and corporate updates. Its business updates describe carbon flat-rolled steel processing, electrical steel laminations, tailor welded products and related capabilities such as galvanizing, pickling, configured blanking, specialty cold reduction and lightweighting.
Worthington Steel news also includes disclosures about material agreements, capital-structure matters and shareholder-related developments when they affect the company’s public reporting. The recurring news record reflects a NYSE-listed Ohio company with steel-processing operations across the United States and international markets.
Energy Vault has signed a Memorandum of Understanding (MOU) with NTPC Limited to establish a long-term partnership focused on deploying Energy Vault's EVx™ gravity-based energy storage technology. This collaboration aims to enhance NTPC's clean energy transition while utilizing coal ash in manufacturing composite blocks for the energy storage system. Energy Vault's CEO, Robert Piconi, emphasized the importance of this partnership in expanding into a significant market and accelerating the clean energy goal globally.
Energy Vault Holdings, Inc. (NYSE: NRGV, NRGV WS) will announce its earnings results for Q1 2022 on May 16, 2022, at 5:00 PM ET. A conference call will follow, accessible via phone or a live webcast. The company focuses on sustainable grid-scale energy storage solutions, employing proprietary technology aimed at reducing energy costs while ensuring reliability. Energy Vault's innovative approach includes using eco-friendly materials to support the transition to a circular economy and clean energy.
Energy Vault Holdings has announced significant leadership appointments to bolster its operational framework. David Hitchcock is appointed as interim Chief Financial Officer, bringing over 30 years of financial leadership, while Kevin Keough becomes Senior Vice President of Corporate Development, focusing on strategic growth initiatives. These additions aim to enhance the company's global financial infrastructure and support its sustainable energy storage solutions, positioning org value="NYSE:NRGV"Energy Vault for future growth in the renewable energy market.
Vicarious Surgical Inc. (NYSE: RBOT) announced it will report financial results for Q1 2022 after market close on May 9, 2022. Management will host a conference call at 4:30 p.m. Eastern Time. Investors can participate by calling +1 (646) 904 5544 for domestic or +1 (929) 526 1599 for international access using code: 646287. The company focuses on enhancing surgical procedures' efficiency and outcomes using proprietary robotic technology. Founded in 2014 and based in Waltham, Massachusetts, Vicarious Surgical is backed by notable investors including Bill Gates.
Volta Inc. (NYSE: VLTA, VLTA WS) reported a strong fourth quarter in 2021, with revenues of $12.1 million, representing a 45% year-over-year increase. Annual revenue surged 66% to $32.3 million. The total number of installed charging stalls rose by 44% to 2,330. Despite the growth in revenue, the company experienced a significant net loss of $121.1 million for Q4 and $276.6 million for the full year. Looking ahead, Volta forecasts 2022 revenues between $70 million and $80 million and plans to add 1,700 to 2,000 new connected stalls.
Sky Harbour Group Corporation has filed its annual report on Form 10-K for 2021, along with a Current Report on Form 8-K/A detailing audited financials for its subsidiary, Sky Harbour LLC. Additionally, a Form S-1 Registration Statement has been submitted for the issuance of 14,519,218 shares of Class A Common Stock linked to public and private warrants. These filings fulfill SEC reporting obligations and provide vital financial data ahead of the business combination that concluded on January 25, 2022.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced the appointment of John Mazzola as vice president of operations. With over 30 years in the medical device industry, Mazzola aims to enhance the company’s manufacturing strategies for its next-generation surgical robotics. Prior to joining Vicarious, he held senior roles at Becton Dickinson, overseeing 10 manufacturing sites. CEO Adam Sachs expressed confidence in Mazzola's expertise to drive operational growth. Mazzola's active involvement in industry associations adds to his credentials.
Vicarious Surgical (NYSE: RBOT, RBOT WS) reported preliminary unaudited financial results for Q4 and the full year 2021. The company experienced a significant increase in operating expenses, totaling $18.2 million in Q4, up 380% year-over-year. Adjusted net loss for Q4 was $18.2 million, or $0.15 per share, compared to a loss of $3.8 million, or $0.04 per share in the prior year. Full year operating expenses reached $38.6 million, reflecting a 197% increase. Cash and cash equivalents stood at $173.5 million as of December 31, 2021.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in two upcoming virtual investor conferences. The Cowen 42nd Annual Healthcare Conference will feature a presentation on Tuesday, March 8, at 9:10 a.m. ET. Additionally, the Oppenheimer 32nd Annual Healthcare Conference is scheduled for Wednesday, March 16, at 8:40 a.m. ET. Interested parties can access live and archived presentations on the company's website. Vicarious Surgical is focused on innovative robotics technology aimed at improving surgical efficiency and patient outcomes.
Alvotech and Fuji Pharma have expanded their strategic partnership to include six biosimilar products aimed at the Japanese market. The agreement grants Fuji exclusive commercial rights to an undisclosed biosimilar in early development, with Alvotech receiving upfront and milestone payments, along with a share of sales. This strengthens Alvotech's position in Japan, the third largest pharmaceutical market globally. The collaboration emphasizes both companies' commitment to enhancing patient access to biosimilars, ultimately contributing to healthcare sustainability.